source
- Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatmentVaderis Therapeutics’ bet that a type of treatment developed for cancers could work for a rare blood disorder is paying off. The 13-person Swiss startup raised $152 million in a Series B to run a ...Endpoints · 41m ago↗ source
- FDA issues early alert after BD needle set defects linked to four deathsThe FDA’s Center for Devices and Radiological Health released an early alert warning clinicians to stop using Becton Dickinson’s intraosseous vascular access needle sets after reports of serious in…